Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil Hydroworld Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Optimi Health Corp (OP: OPTHF ) 0.1630 +0.0097 (+6.33%) Streaming Delayed Price Updated: 12:22 PM EDT, Nov 1, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Optimi Health Corp < Previous 1 2 Next > Psychedelic Biotech Psyence Grows Pipeline With Trials And Psilocybin Drug Developer Acquisition September 16, 2024 Psyence Biomed launches Phase IIb trials for psilocybin in palliative care and Alcohol Use Disorder, bolstering its clinical pipeline with key acquisitions and partnerships. Via Benzinga New Milestone In Psychedelics Market: Canadian Start-Up Will Export Psilocybin And MDMA To Australia June 05, 2024 Canada Magic Mushrooms and MDMA market is hitting new milestones as canada has licensed Optimi to export psilocybin and MDMA to Australia Via Benzinga Psychedelics Headlines: Dementia Prevention, Psychological Flexibility, Ancient Romans' Trips And More April 17, 2024 Via Benzinga Psyched: DEA Revisits Ban On Two Psychedelics, Farewell Russell Newcombe, Podcast Episode On Kanna & More April 17, 2024 Via Benzinga Optimi To Supply Psilocybin For New Zealand's Mātai Medical Research Institute April 09, 2024 Via Benzinga Two Top Biotechs Forge MDMA Supply Deals For Clinical Research March 26, 2024 Via Benzinga Psychedelics Headlines: Substitution Survey, Frank Herbert's Magic Mushrooms, Celestial Plans And News Review March 16, 2024 Via Benzinga Psychedelics Headlines: Predicting Readiness, Correcting The Hype, Good And Bad Drugs, Training Programs And More March 01, 2024 Via Benzinga Psychedelics Headlines: Anti-inflammatory Effects, Global Drug Survey, 'Synthetic Surprise,' UK's Harm Reduction Hub And More January 26, 2024 Discover the latest research on psychedelics, from anti-inflammatory effects to end-of-life therapy. New journal issue and online course available. Via Benzinga Psychedelics Headlines: Magic Mushrooms For Sexual Wellbeing, The DEA's Stance, The Therapist's Role & More January 08, 2024 Welcome to Benzinga's weekly psychedelics news roundup. We have pulled together several must-read news items from the last week of December 2023 and the first of January 2024. Via Benzinga Psyched: Psilocybin Therapy For Depression, UK Rescheduling, US Policy Reform And More September 11, 2023 Single Psilocybin Dose 'Significantly' Reduces Major Depression Symptoms, An AI Predictive Model, And UK’s Struggle For Reclassification Via Benzinga Topics Artificial Intelligence Exposures Artificial Intelligence Optimi Health Will Supply Psychedelics To Canada's SAP, Secures CA$1M Private Financing September 08, 2023 Health Canada has approved an amendment to Optimi Health’s (OTCQX: OPTHF) dealer's license, effectively allowing the company to supply MDMA and psilocybin drugs to the country’s Special Access Program... Via Benzinga Psyched: Professional Practice Guidelines, DMT For Stroke, Dua Lipa &. Amanda Feilding, Clinical Results & More August 14, 2023 First Ever Professional Practice Guidelines For Psychedelic-Assisted Therapy Published Via Benzinga Natural Psilocybin Companies Diversify: Latest By Optimi, Red Light Holland And A European Player August 01, 2023 Optimi Completes Novel Extraction Process and Files U.S. Prov. Patent Via Benzinga MDMA Deals: Optimi Supplies Numinus-MAPS Program & PharmAla Exports To Australian University June 20, 2023 Numinus Wellness (OTCMKTS: NUMIF) with support from the Multidisciplinary Association for Psychedelic Studies (MAPS) will utilize Optimi Health’s (OTCMKTS: OPTHF) Good Manufacturing Practice... Via Benzinga Psyched: New Psilocybin Forms, LSD Anxiety Study, UK's Parliamentary Debate And More May 23, 2023 Biotech Company Discovers What May Be The First New Compounds Of Psilocybin In History NY-based biotech platform Terran Biosciences announced the publication of an international PCT patent application... Via Benzinga The Psychedelic Mushrooms Market; Between Legitimate Harvesting And Illegal Retail Sales May 17, 2023 While psychedelics reform is clearly gaining momentum, not only in the U.S. but notably in places like Australia and less so Canada. The fact is, all compounds remain currently Schedule I drugs (or... Via Benzinga Psyched: $20M Research Fund, LSD Microdosing For Cancer, MEAI Enters Clinical Stage, Reform Update & More May 15, 2023 Researchers At Johns Hopkins Get $20M Fund Prompted By Longtime Psychedelics Scientist Johns Hopkins University academics received a boost in funding thanks to the recently launched Roland R. Griffiths... Via Benzinga Optimi Health Boosts Psilocybin Production With New Health Canada License And Supply Deal May 11, 2023 Psychedelics research and manufacturing company Optimi Health Corp. (OTCQX: OPTHF) received a “Natural Health Product Site" license, adding to its existing permits to produce and supply psychedelic... Via Benzinga What To Expect From The Benzinga Psychedelics Capital Conference, The Must-Attend Event For This Emerging Industry April 03, 2023 The world of psychedelics is evolving rapidly, and the Benzinga Psychedelics Capital Conference is the premier event for those who want to be part of this exciting journey. Via Benzinga Psyched: 9 US Reform Bills, Ayahuasca 'A Release' For Prince Harry, At-Home Therapy & More March 07, 2023 Psychedelics Bills Around The Country: 9 New Proposals, Several Passes, Several Fails And A Successful Local Decriminalization Throughout the 2023 session, numerous discussions have been... Via Benzinga Australia Receives First Batch Of Clinical-Grade Psilocybin From Mindset Pharma And PharmAla March 06, 2023 The exclusive sales partnership between psychedelics biotechs Mindset Pharma (OTCQB: MSSTF) and PharmAla Holdings resulted in the first sale of Mindset’s GMP-compliant psilocybin in Australia. Via Benzinga Latest Psychedelics Deals: Optimi Supplies Australia, Awakn Partners Licensing In California March 02, 2023 Optimi Health Enters Australian Medical Psychedelics Market Via Mind Medicine Australia Via Benzinga Psyched: 12 States Discuss Legalization Bills, Ceremonies For Veterans With TBI, Ketamine And MDMA Fast-Tracks & More February 13, 2023 Psychedelics Legislation: The Latest On Hawaii, Virginia, Missouri & More Via Benzinga How Do Psilocybin And MDMA Work Together? This Proposed Experiential Study Is Set To Find Out February 09, 2023 Licensed psychedelic drugs producer Optimi Health Corp. (OTCQX: OPTHF) submitted a Health Canada clinical trial application (CTA) for a Phase 1 study that will assess the safety of combining its... Via Benzinga MDMA News: Optimi's New Drug Now Available, Revive Advances Transdermal Patch Evaluations February 06, 2023 Considering MDMA will likely be the first psychedelic to receive FDA approval for psychotherapeutic use to treat serious mental health conditions such as PTSD, seve Via Benzinga Psyched: States With Psychedelics Legalization Bills, Next-Gen Molecule For Addiction Treatment And More January 25, 2023 Legalizing Psychedelics From New York To Washington And Five In Between: Which State Will Go First? Via Benzinga Here Are The Latest Psychedelics Partnerships From Production & Supply Chain To Community Action January 21, 2023 Let’s do a quick tour of some of the latest announcements made by psychedelics companies over the past week. We promise you’ll be informed in less time than it takes to brew your coffee. New,... Via Benzinga Canada Update: Psychedelics Legal Landscape, Overview & Near-Term Predictions October 20, 2022 Canada is hosting discussions on legal access to psychedelic-assisted therapies, especially after Alberta passed regulatory measures for this type of health s Via Benzinga Optimi Health Announces C$3.27 Million Private Placement with Strategic Investment from Lululemon Founder Chip Wilson October 12, 2022 Optimi Health Corp. (CSE:OPTI) (OTCQX:OPTHF) is a Canadian-based company licensed by Health Canada to produce and supply natural, EU-GMP-grade psilocybin, synthetic psychedelic substances and... Via PressReach < Previous 1 2 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
